
Visual acuity suppression: Difference between revisions
>Dextromethorphan image missing? someone correct please if anyone has it just pointing it out |
>Josikins fixed missing image |
||
Line 1: | Line 1: | ||
<onlyinclude> | <onlyinclude> | ||
[[File:London acuity suppression.jpg|300px|thumb|right|''Blurry London by [[User:Josikins|Josikins]]'' - This image serves as an accurate replication of acuity suppression as seen from the golden jubilee footbridge in central London.]] | |||
'''Acuity suppression''' can be described as the experience of a person's sense of vision becoming partially to completely blurred and indistinct.<ref>Hollister L. E. (1984). Effects of hallucinogens in humans,” in Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives, ed Jacobs B. L., editor. (New York, NY: Raven Press), 19–33.</ref><ref>Masters R. E. L. (1966). The Varieties of Psychedelic Experience. New York, NY: Henry Holt & Company, Inc.</ref><ref>Nichols D. E. (2004). Hallucinogens. Pharmacol. Ther. 101, 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref> This effect may affect the entirety of the person's vision or specific sections of it. Depending on its intensity, this can often result in a reduced ability to function and perform basic tasks which necessitate the use of sight. | '''Acuity suppression''' can be described as the experience of a person's sense of vision becoming partially to completely blurred and indistinct.<ref>Hollister L. E. (1984). Effects of hallucinogens in humans,” in Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives, ed Jacobs B. L., editor. (New York, NY: Raven Press), 19–33.</ref><ref>Masters R. E. L. (1966). The Varieties of Psychedelic Experience. New York, NY: Henry Holt & Company, Inc.</ref><ref>Nichols D. E. (2004). Hallucinogens. Pharmacol. Ther. 101, 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002</ref><ref>Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346</ref> This effect may affect the entirety of the person's vision or specific sections of it. Depending on its intensity, this can often result in a reduced ability to function and perform basic tasks which necessitate the use of sight. | ||
Revision as of 19:11, 28 February 2018

Acuity suppression can be described as the experience of a person's sense of vision becoming partially to completely blurred and indistinct.[1][2][3][4] This effect may affect the entirety of the person's vision or specific sections of it. Depending on its intensity, this can often result in a reduced ability to function and perform basic tasks which necessitate the use of sight.
Acuity suppression is often accompanied by other coinciding effects such as double vision[5] and pattern recognition suppression. This effect is most commonly induced under the influence of moderate dosages of depressant and dissociative compounds, such as alcohol, quetiapine, ketamine, and DXM.
Psychoactive substances
Compounds within our psychoactive substance index which may cause this effect include:
- 3,4-CTMP
- 3-Cl-PCP
- 3-HO-PCE
- 3-HO-PCP
- 3-MeO-PCE
- 3-MeO-PCMo
- 3-MeO-PCP
- 4-HO-DPT
- 4-MeO-PCP
- 5-MeO-DMT
- 5F-PB-22
- A-PHP
- A-PVP
- Alcohol
- Alprazolam
- Amanita muscaria
- Benzydamine
- Bromazepam
- Bufotenin
- Cannabis
- Carisoprodol
- Clonazepam
- Clonazolam
- Datura
- Deschloroketamine
- Dextromethorphan
- Diazepam
- Diphenhydramine
- Diphenidine
- Ephenidine
- Eszopiclone
- Experience:3-MeO-PCP, LSD, Clonazolam, and Amphetamine - Excessive Amounts and Excessive Confusion
- Flualprazolam
- GBL
- GHB
- Gaboxadol
- HXE
- JWH-018
- JWH-073
- Ketamine
- Kratom
- MXiPr
- Memantine
- Mephenaqualone
- Methaqualone
- Methoxetamine
- Methoxphenidine
- Mirtazapine
- Myristicin
- Nitrous
Experience reports
Anecdotal reports which describe this effect within our experience index include:
- Experience: 550mg DPH - My First Time on DPH
- Experience:100ug 1P-LSD - A Fear and loathing into Bliss
- Experience:200 mg of MXP + N2O:20 chargers
- Experience:250 seeds - Harsh body load
- Experience:25mg Deschloroketamine - My first time orally dosing DCK
- Experience:3-MeO-PCP - Extreme psychosis
- Experience:3-MeO-PCP, LSD, Clonazolam, and Amphetamine - Excessive Amounts and Excessive Confusion
- Experience:3g Syrian Rue + 5g Acacia Confusa - Life Changing Madness
- Experience:60mg Zolpidem - A Delirious Adventure
- Experience:DXM & DPH in combination
- Experience:Datura Alcoholic Tincture
- Experience:Mushrooms (~0.5 g) - Autonomous Voice
- Experience:Unknown dose - Supermarket dislocation and biking
See also
- Responsible use
- Subjective effects index
- Acuity enhancement
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
- Psychedelics - Subjective effects
External links
References
- ↑ Hollister L. E. (1984). Effects of hallucinogens in humans,” in Hallucinogens: Neurochemical, Behavioral and Clinical Perspectives, ed Jacobs B. L., editor. (New York, NY: Raven Press), 19–33.
- ↑ Masters R. E. L. (1966). The Varieties of Psychedelic Experience. New York, NY: Henry Holt & Company, Inc.
- ↑ Nichols D. E. (2004). Hallucinogens. Pharmacol. Ther. 101, 131–181. https://doi.org/10.1016/j.pharmthera.2003.11.002
- ↑ Gallimore, A. R. (2015). Restructuring consciousness–the psychedelic state in light of integrated information theory. Frontiers in human neuroscience, 9, 346. https://dx.doi.org/10.3389%2Ffnhum.2015.00346
- ↑ Smith, J. L., & Buncic, J. R. (1999). Drugs which can affect near vision: a useful list. American Orthoptic Journal, 49, 180-190. https://uwpress.wisc.edu/journals/pdfs/AOJ_49_178.pdf